Skye Bioscience (SKYE) FCF Margin (2013 - 2014)
Skye Bioscience (SKYE) posted quarterly FCF Margin of 0.61% for Q2 2014, up 224.0% year-over-year from 0.19% in Q2 2013, and up 94.22% quarter-over-quarter from 10.57% in Q4 2013.
Skye Bioscience (SKYE) FCF Margin (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported FCF Margin for 2 consecutive years, with 0.61% the latest figure, recorded in Q2 2014.
- In Q2 2014, FCF Margin rose 224.0% year-over-year to 0.61%; the TTM figure through Apr 2014 stood at 0.33% (changed N/A YoY), while the FY2013 annual figure was 18.71%, down 3058.0% from the prior year.
- FCF Margin rose to 0.61% in Q2 2014 per SKYE's latest filing, from 10.57% in the prior quarter.
- Across five years, FCF Margin topped out at 9.01% in Q3 2013 and bottomed at 104.95% in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2014 | -0.61% |
| Oct 31, 2013 | -10.57% |
| Jul 31, 2013 | 9.01% |
| Apr 30, 2013 | -2.85% |
| Jan 31, 2013 | -104.95% |